Ophthalmology · Clinical trials
Diabetic Macular Oedema Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About diabetic macular oedema — and why its trials are hard
Diabetic macular oedema (DME) is the most common cause of vision loss in people with diabetic retinopathy, caused by VEGF-driven breakdown of the blood-retinal barrier and accumulation of fluid in the central macula. Vision loss correlates with central subfield thickening on optical coherence tomography (OCT). Historically managed with focal/grid laser, DME care was transformed by intravitreal anti-VEGF therapy. Ranibizumab (RISE/RIDE) and aflibercept (VISTA/VIVID) delivered large, sustained gains in best-corrected visual acuity (BCVA) versus laser. Faricimab, a bispecific anti-VEGF-A/anti-Ang-2 antibody (YOSEMITE/RHINE), matched aflibercept on vision while extending dosing to every 16 weeks in many patients. High-dose aflibercept 8 mg (Eylea HD, PHOTON) further lengthens intervals. Corticosteroid implants (dexamethasone Ozurdex, fluocinolone Iluvien) address the inflammatory component and suit pseudophakic or anti-VEGF-refractory eyes, at the cost of cataract and intraocular-pressure rise. Endpoints centre on mean BCVA letter change and the proportion gaining ≥15 letters, alongside anatomical drying on OCT.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| aflibercept (Eylea) | 2014 | Diabetic macular oedema | VISTA and VIVID | Mean change in BCVA (ETDRS letters) at week 52 vs laser | VISTA +12.5 and VIVID +10.7 letters vs ~+0.2 to +1.2 with laser control |
| ranibizumab (Lucentis) | 2012 | Diabetic macular oedema | RISE and RIDE | Proportion gaining ≥15 letters at 24 months | ~34–45% gained ≥15 letters with ranibizumab vs ~12–18% sham; mean gain ~+10.9 to +12.5 letters |
| faricimab (Vabysmo) | 2022 | Diabetic macular oedema | YOSEMITE and RHINE | Mean BCVA change at year 1; non-inferiority vs aflibercept | ~+10.7 to +11.6 letters, non-inferior to aflibercept, with over half of patients on every-16-week dosing |
| aflibercept 8 mg (Eylea HD) | 2023 | Diabetic macular oedema (extended dosing) | PHOTON | Mean BCVA change at week 48; non-inferiority vs aflibercept 2 mg | 8 mg every 12–16 weeks non-inferior to 2 mg every 8 weeks (~+8 to +9 letters), fewer injections |
| dexamethasone intravitreal implant (Ozurdex) | 2014 | Diabetic macular oedema (corticosteroid) | MEAD | Proportion gaining ≥15 letters over 3 years | ~22% gained ≥15 letters vs ~12% sham; higher rates of cataract and raised IOP |
| fluocinolone acetonide implant (Iluvien) | 2014 | Diabetic macular oedema (chronic, sustained-release) | FAME A and B | Proportion gaining ≥15 letters at month 24/36 | ~28–29% gained ≥15 letters vs ~16% sham over 3 years |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in diabetic macular oedema development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| brolucizumab — KESTREL and KITE | Met non-inferiority vs aflibercept on BCVA, and was FDA-approved for DME in 2022, but uptake was undermined by intraocular inflammation and retinal vasculitis/occlusion safety signals | Rare but serious immune-mediated occlusive retinal vasculitis (first flagged in nAMD) limited clinical adoption despite meeting efficacy endpoints |
| bevasiranib (VEGF siRNA) — COBALT (and the nAMD CARBON/COBALT program) | Development for DME/retinal disease halted for lack of efficacy | siRNA silenced VEGF production too slowly to control established oedema; no meaningful visual benefit over comparators |
Choosing the right endpoint
Primary endpoints that matter in diabetic macular oedema trials
- Mean BCVA change (ETDRS letters) — Primary functional endpoint in nearly all DME pivotal trials; ~5 letters is broadly clinically meaningful
- Proportion gaining ≥15 letters — Responder analysis (three lines of vision) used in RISE/RIDE and steroid implant trials
- Central subfield thickness (OCT) — Anatomical marker of macular drying; supports functional endpoints and guides retreatment
- Durability / treatment interval — Proportion achieving extended dosing (e.g. Q12–Q16W) is a key differentiator for faricimab and aflibercept 8 mg
How iNGENū runs diabetic macular oedema trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Diabetic Macular Oedema clinical trials — FAQs
How much vision can anti-VEGF restore in DME?
When are steroid implants preferred over anti-VEGF?
Do newer agents reduce injection burden?
Ready to discuss your diabetic macular oedema trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal